The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.

PubWeight™: 0.88‹?›

🔗 View Article (PMID 26651333)

Published in BMC Pulm Med on December 10, 2015

Authors

Ashley Woodcock1, Nawar Diar Bakerly2, John P New3, J Martin Gibson4, Wei Wu5, Jørgen Vestbo6, David Leather7

Author Affiliations

1: Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. ashley.woodcock@manchester.ac.uk.
2: Salford Royal NHS Foundation Trust, Salford, UK. nawar.bakerly@srft.nhs.uk.
3: Salford Royal NHS Foundation Trust, Salford, UK. john.new@manchester.ac.uk.
4: Salford Royal NHS Foundation Trust, Salford, UK. Martin.Gibson@manchester.ac.uk.
5: GlaxoSmithKline, Research Triangle Park, Durham, NC, USA. wei.w.wu@gsk.com.
6: Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. jorgen.vestbo@manchester.ac.uk.
7: GSK Respiratory Centre of Excellence, GlaxoSmithKline UK Ltd, Uxbridge, UK. david.a.leather@gsk.com.

Associated clinical trials:

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma | NCT01706198